JP7659648B2 - ピラゾロピリジン誘導体及びその使用 - Google Patents

ピラゾロピリジン誘導体及びその使用 Download PDF

Info

Publication number
JP7659648B2
JP7659648B2 JP2023556474A JP2023556474A JP7659648B2 JP 7659648 B2 JP7659648 B2 JP 7659648B2 JP 2023556474 A JP2023556474 A JP 2023556474A JP 2023556474 A JP2023556474 A JP 2023556474A JP 7659648 B2 JP7659648 B2 JP 7659648B2
Authority
JP
Japan
Prior art keywords
alkyl
pharma
cycloalkyl
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023556474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509981A (ja
JP2024509981A5 (cg-RX-API-DMAC7.html
Inventor
ボナッツィ,シモーネ
セルニジェンコ,アルチョーム
ストロカ コブ,ジェニファー
アリシア デイルズ,ナタリー
デューハースト,ジャネッタ
ジェイムス ヘッセ,マシュー
ジャイン,ラマ
リャン ケリガン,ジョン
アーメッド マリク,ハスナイン
アール. マニング,ジェイムス
オーブリエン,ゲイリー
ダブリュ. パターソン,アンドリュー
マリー-フランス トムセン,ノエル
ワイエフ ティン,パメラ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2024509981A publication Critical patent/JP2024509981A/ja
Publication of JP2024509981A5 publication Critical patent/JP2024509981A5/ja
Priority to JP2025056015A priority Critical patent/JP2025106341A/ja
Application granted granted Critical
Publication of JP7659648B2 publication Critical patent/JP7659648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023556474A 2021-03-15 2022-03-14 ピラゾロピリジン誘導体及びその使用 Active JP7659648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025056015A JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161139P 2021-03-15 2021-03-15
US63/161,139 2021-03-15
US202163164130P 2021-03-22 2021-03-22
US63/164,130 2021-03-22
PCT/IB2022/052281 WO2022195454A1 (en) 2021-03-15 2022-03-14 Pyrazolopyridine derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025056015A Division JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Publications (3)

Publication Number Publication Date
JP2024509981A JP2024509981A (ja) 2024-03-05
JP2024509981A5 JP2024509981A5 (cg-RX-API-DMAC7.html) 2024-03-28
JP7659648B2 true JP7659648B2 (ja) 2025-04-09

Family

ID=80819999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023556474A Active JP7659648B2 (ja) 2021-03-15 2022-03-14 ピラゾロピリジン誘導体及びその使用
JP2025056015A Pending JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025056015A Pending JP2025106341A (ja) 2021-03-15 2025-03-28 ピラゾロピリジン誘導体及びその使用

Country Status (20)

Country Link
US (4) US11787785B2 (cg-RX-API-DMAC7.html)
EP (1) EP4308562A1 (cg-RX-API-DMAC7.html)
JP (2) JP7659648B2 (cg-RX-API-DMAC7.html)
KR (1) KR102902295B1 (cg-RX-API-DMAC7.html)
AU (2) AU2022239950B2 (cg-RX-API-DMAC7.html)
CA (1) CA3208951A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002726A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013486A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230486A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000188A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076800A (cg-RX-API-DMAC7.html)
IL (1) IL305931A (cg-RX-API-DMAC7.html)
JO (1) JOP20230218A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010827A (cg-RX-API-DMAC7.html)
PE (1) PE20242203A1 (cg-RX-API-DMAC7.html)
PY (1) PY2217419A (cg-RX-API-DMAC7.html)
TW (1) TWI923713B (cg-RX-API-DMAC7.html)
UY (1) UY39671A (cg-RX-API-DMAC7.html)
WO (1) WO2022195454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307290B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021255160B2 (en) 2020-04-13 2024-02-01 Aptabio Therapeutics Inc. Pulmonary fibrosis medicine containing pyrazole derivative
EP4308559A1 (en) * 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
PE20240822A1 (es) 2021-03-22 2024-04-18 Neurocrine Biosciences Inc Inhibidores de vmat2 y metodos de uso
CN120129677A (zh) 2022-11-04 2025-06-10 百时美施贵宝公司 化合物及其用于治疗血红素病变的用途
WO2024255810A1 (en) * 2023-06-15 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd Dihydropyrimidine-2, 4 (1h, 3h) -dione-containing polycyclic derivatives and pharmaceutical composition thereof, preparation method thereof and use thereof
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513164A (ja) 2003-12-02 2007-05-24 セルジーン・コーポレーション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2020531498A (ja) 2017-08-23 2020-11-05 ノバルティス アーゲー 3−(1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオン誘導体及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
CN102089291B (zh) 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
JP2020009513A (ja) * 2018-07-10 2020-01-16 キオクシア株式会社 メモリシステム
AR116109A1 (es) * 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR102980990B1 (ko) 2019-04-05 2026-06-25 카이메라 쎄라퓨틱스 인코포레이티드 Stat 분해제 및 이의 용도
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4100394B1 (en) 2020-02-04 2026-04-08 Stingray Therapeutics, Inc. Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof
US20230089530A1 (en) 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513164A (ja) 2003-12-02 2007-05-24 セルジーン・コーポレーション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
JP2020531498A (ja) 2017-08-23 2020-11-05 ノバルティス アーゲー 3−(1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオン誘導体及びその使用
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation

Also Published As

Publication number Publication date
PE20242203A1 (es) 2024-11-19
ZA202307290B (en) 2024-09-25
TW202304900A (zh) 2023-02-01
AU2022239950B2 (en) 2024-09-12
AU2022239950A1 (en) 2023-08-31
MX2023010827A (es) 2023-09-28
CL2023002726A1 (es) 2024-04-01
BR112023018542A2 (pt) 2023-10-10
EP4308562A1 (en) 2024-01-24
US20250282762A1 (en) 2025-09-11
JP2024509981A (ja) 2024-03-05
AU2024278210A1 (en) 2025-01-02
UY39671A (es) 2022-10-31
CA3208951A1 (en) 2022-09-22
AU2024278210B2 (en) 2026-03-26
DOP2023000188A (es) 2023-11-15
PY2217419A (es) 2022-09-27
WO2022195454A1 (en) 2022-09-22
NZ802195A (en) 2025-10-31
IL305931A (en) 2023-11-01
JOP20230218A1 (ar) 2023-09-14
ECSP23076800A (es) 2023-11-30
KR102902295B1 (ko) 2025-12-23
US20250002479A1 (en) 2025-01-02
US20240158374A1 (en) 2024-05-16
US12172984B2 (en) 2024-12-24
CO2023013486A2 (es) 2023-11-10
KR20230156766A (ko) 2023-11-14
US11787785B2 (en) 2023-10-17
US12252482B2 (en) 2025-03-18
US20230108325A1 (en) 2023-04-06
TWI923713B (zh) 2026-05-01
CR20230486A (es) 2024-01-25
JP2025106341A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
EP4076650B1 (en) 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR102902295B1 (ko) 피라졸로피리딘 유도체 및 이의 용도
US12103919B2 (en) 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20250276964A1 (en) Benzisoxazole Derivatives and Uses thereof
CN116802182A (zh) 吡唑并吡啶衍生物及其用途
BR122025004894B1 (pt) Uso de derivados de pirazolopiridina, e kit
BR112023018542B1 (pt) Derivados de pirazolopiridina, e composição e combinação farmacêuticas
BR122025004894A2 (pt) Derivados de pirazolopiridina, seus usos, composição e combinação farmacêuticas, e kit
EA051403B1 (ru) Производные пиразолопиридина и пути их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240306

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250328

R150 Certificate of patent or registration of utility model

Ref document number: 7659648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150